![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, February 10, 2014 8:38:14 AM
ScripsAmerica's RapiMed Product Receives Registration Approval From the Hong Kong Government
Company's RapiMed(R) Children's Pain Reliever and Fever Reducer Can Now be Sold and Distributed Throughout Hong Kong
TYSONS CORNER, Va., Feb. 10, 2014 (GLOBE NEWSWIRE) -- ScripsAmerica, Inc. (OTCBB:SCRC) today announced that the Company has received registration approval for its RapiMed® Children's Pain Reliever & Fever Reducer from the Government of Hong Kong.
With the registration process complete, ScripsAmerica is now free to distribute RapiMed® throughout Hong Kong and the Company is ready to accept orders from affiliate hospital networks, and representatives of a major health product retailer with over 2,000 stores and over 500 pharmacies. Because RapiMed® is an over-the-counter (OTC) medication, it does not require FDA approval in order to be sold in Hong Kong due to the fact that its manufacturer is CGMP (Current Good Manufacturing Practices) certified.
With this certification, RapiMed®'s manufacturer needs only to follow the monograph process for the product's active ingredient. A monograph defines the safety, effectiveness, and labeling of all marketing OTC active ingredients and once a final monograph is completed, companies can make and market an OTC product without the need for FDA pre-approval.
Bob Schneiderman, CEO of ScripsAmerica, states "ScripsAmerica is very excited to announce RapiMed's registration approval by the Government of Hong Kong to allow the distribution of our children's pain reliever. Now the company can focus all of its efforts on finalizing distribution agreements with a large affiliate hospital network and major health product retailer to sell our product throughout Greater Asia."
"We believe that our product's unique and innovative rapid melt technology will lead to tremendous success in the Chinese OTC pharmaceutical market which will lead to expansion into other international markets, including new OTC drugs using our proprietary RapiMed formulation. This is a major milestone for ScripsAmerica that we believe is the beginning of significant revenue growth and increased shareholder value," Schneiderman continued.
About ScripsAmerica, Inc.
ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit www.ScripsAmerica.com
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM